Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Novel Oncology Drugs in Clinical Development in JAPAN

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Daiichi Sankyo Co Ltd

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              JAPAN Japan

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BIO IMPACT

              Participation Not Confirmed

              Update your events

              Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062 in Combination with KEYTRUDA in Lung Cancer

              Contact the Supplier

              Lead Product(s): DS-1062,Pembrolizumab

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: Merck & Co. Inc.

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration May 29, 2020

              Details:

              Strategic research collaboration aims at to evaluating the combination of DS-1062, a TROP2 directed DXd antibody drug conjugate, and KEYTRUDA in patients with previously-treated advanced or metastatic non-small cell lung cancer without actionable genomic alterations.

              Taiho Pharmaceutical

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              JAPAN Japan

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BIO IMPACT

              Participation Not Confirmed

              Update your events

              Merck Establishes Strategic Oncology Collaboration with Taiho and Astex

              Contact the Supplier

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Small molecule

              Partner/Sponsor/Collaborator: Merck & Co. Inc.

              Deal Size: $2,550.0 million Upfront Cash: $50.0 million

              Deal Type: Collaboration January 06, 2020

              Details:

              Under the terms of the agreement, Merck, Taiho and Astex will combine preclinical candidates and their data with knowledge and expertise from their respective research programs.

              PharmaCompass__DigitalAd